Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 601 - 625 of 14608 in total

Factor XIII (human)

Factor XIII (human) is a heat-treated, lyophilized concentrate of coagulation factor XIII, an endogenous enzyme responsible for the crosslinking of fibrin and an essential component of the coagulation cascade [FDA Label]. For people with congenital deficiency or mutation of Factor XIII, a rare bleeding disorder, exogenous replacement of this key...
Approved
Investigational
Matched Description: … and maintenance of hemostasis [A18581]. ... in adult and pediatric patients with congenital FXIII deficiency [FDA Label]. ... in increased mechanical strength and resistance to fibrinolysis of the fibrin clot. …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …

Nonacog beta pegol

Nonacog beta pegol is a recombinant coagulation factor IX derivative. It is produced without animal-derived materials and with an attached 40kDa polyethylene glycol (PEG) molecule for peptide activation by a site-directed glycoPEGylation. Once activated, the activation molecule with PEG is cleaved to leave the activated factor IX (Factor IXa). Nonacog...
Approved
Investigational
Matched Description: … It is produced without animal-derived materials and with an attached 40kDa polyethylene glycol (PEG) ... [A31496] Nonacog beta pegol was developed by Novo Nordisk and received its first global approval by the …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …

Thioredoxin

Thioredoxin is a small dithiol protein and specific reductant for major allergenic proteins present in foods from animal and plant products. It is a 12-kD oxidoreductase enzyme encoded by TXN and TXN2 genes that contains a dithiol-disulfide active site. It plays an essential role as an antioxidant in neutralizing food...
Approved
Matched Description: … foods from animal and plant products. ... Thioredoxin is a small dithiol protein and specific reductant for major allergenic proteins present in ... It plays an essential role as an antioxidant in neutralizing food allergens and redox signalling. …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Exagamglogene autotemcel

Sickle cell disease (SCD) is a genetic disorder characterized by the production of abnormal sickle-shaped red blood cells (called hemoglobin S, HbS) that initiate a pathophysiology resulting in severe pain, progressive multi-organ damage, and premature death. Treatment options for SCD are largely focused on preventing the production and circulation of...
Approved
Investigational
Matched Description: … [A262691] Treatment options for SCD are largely focused on preventing the production and circulation ... ] - a mainstay of treatment since the 1990s - as well as newer agents like [crizanlizumab] and [voxelotor ... [L10139] Following engraftment, it causes an increase in the production of HbF and a subsequent decrease …
Matched Categories: … Blood and Blood Forming Organs …

Motixafortide

Motixafortide is a cyclic peptide hematopoietic stem cell mobilizer used to improve stem cell collection prior to autologous transplantation. Hematopoietic stem cell transplantation (HSCT) is commonly employed in the context of hematologic cancers - high-dose chemotherapy regimens destroy cancerous blood cells, which are then replaced via infusion of the patient's...
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins …

Rilonacept

Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome...
Approved
Investigational
Matched Description: … Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old. ... Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein ... Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Burosumab

Burosumab (KRN23) is an entirely human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic rickets . The U.S. Food and Drug Administration approved Crysvita (burosumab) in April 2018. This is the first drug approved...
Approved
Investigational
Matched Description: … It causes impaired bone growth and development in children and adolescents and issues with bone mineralization ... This is the first drug approved to treat adults and children ages 1 year and older with X-linked hypophosphatemia ... Food and Drug Administration approved Crysvita (burosumab) in April 2018. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Drugs Affecting Bone Structure and Mineralization …

Treprostinil

Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease.[L41855,L41860] The first agent approved for the treatment...
Approved
Investigational
Matched Description: … systemic arterial vascular beds and the inhibition of platelet aggregation. ... is a stable tricyclic analogue of prostacyclin[A248770] that promotes the vasodilation of pulmonary and ... [L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and …
Matched Categories: … Blood and Blood Forming Organs …

Nilutamide

Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of...
Approved
Investigational
Matched Description: … the growth of normal and malignant prostatic tissue. ... Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate ... Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Aceclofenac

Aceclofenac is an oral non-steroidal anti-inflammatory drug (NSAID) with marked anti-inflammatory and analgesic properties used to treat osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. It is reported to have a higher anti-inflammatory action or at least comparable effects than conventional NSAIDs in double-blind studies [A19667, A19668, A19670]. Aceclofenac potently inhibits the...
Approved
Investigational
Matched Description: … Aceclofenac is an oral non-steroidal anti-inflammatory drug (NSAID) with marked anti-inflammatory and ... analgesic properties used to treat osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. ... displays high permeability to penetrate into synovial joints where in patients with osteoarthritis and …
Matched Categories: … Acetic Acid Derivatives and Related Substances ... Antiinflammatory and Antirheumatic Products ... Topical Products for Joint and Muscular Pain ... Antiinflammatory and Antirheumatic Products, Non-Steroids …

Sotalol

Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening...
Approved
Matched Description: … injection indicated for life threatening ventricular arrhythmias and maintaining normal sinus rhythm ... [L6334] A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous …
Matched Categories: … sotalol and thiazides ... Beta Blocking Agents and Thiazides ... sotalol and acetylsalicylic acid ... Beta Blocking Agents, Non-Selective, and Thiazides …

Simethicone

Simethicone is a silicon based surfactant that decreases the surface tension of gastrointestinal gas bubbles to facilitate their elimination. It has a favourable safety profile as it is not systemically absorbed. Simethicone has been in use since the 1940s but was granted FDA approval in 1952.
Approved
Matched Mixtures name: … Gelusil Antacid and Anti-gas …

Polatuzumab vedotin

Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to...
Approved
Investigational
Matched Description: … humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and ... [L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Lorazepam

Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.
Approved
Matched Description: … Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic ... [A957] It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in …
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepine hypnotics and sedatives ... Benzodiazepines and benzodiazepine derivatives …

Chlorpropamide

Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class...
Approved
Investigational
Matched Description: … increase the number and sensitivity of insulin receptors. ... Renal and hepatic dysfunction may increase the risk of hypoglycemia. ... Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. …
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Papaverine

An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear,...
Approved
Investigational
Matched Description: … It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, ... mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and …
Matched Categories: … Alimentary Tract and Metabolism ... Papaverine and Derivatives ... Genito Urinary System and Sex Hormones …

Hemoglobin

The respiratory protein of the red blood cells. It consists primarily of globin and heme.
Approved
Experimental
Investigational
Matched Description: … It consists primarily of globin and heme. …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Susoctocog alfa

Intravenous susoctocog alfa is a recombinant, B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) product that has recently been approved for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA). AHA is a rare bleeding disorder that results in a prolonged clotting time as measured by the...
Approved
Investigational
Matched Description: … These autoantibodies neutralize circulating human factor VIII and create a functional deficiency of this ... Susoctocog alfa was approved by the FDA in October 2014 and is marketed under the brand name Obizur for ... porcine FVIII treatment approved for AHA that allows physicians to manage the treatment's efficacy and …
Matched Categories: … Blood and Blood Forming Organs …

Migalastat

Fabry disease is a rare, progressive genetic disorder characterized by a defective GLA gene that causes a deficiency in the enzyme alpha-Galactosidase A (alpha-Gal A). This enzyme is responsible for breaking down glycosphingolipid substrate that, when deficient in patients with Fabry disease, builds up in the blood vessels, the kidneys,...
Approved
Investigational
Matched Description: … in patients with Fabry disease, builds up in the blood vessels, the kidneys, the nerves, the heart, and ... L4274,L4278] In the U.S., it is estimated that more than 3,000 people are living with Fabry disease, and ... [L4274] Given the rarity of Fabry disease and the proportion of Fabry disease patients that could …
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …

Ibrutinib

Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in...
Approved
Matched Description: … It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies ... [A32299] Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 ... [L45894] Ibrutinib was approved by the EMA in October 2014 [L45884] and by Health Canada in November …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Dostarlimab

Dostarlimab is an IgG4 humanized monoclonal antibody targeted against the human programmed death receptor-1 (PD-1). PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the anti-tumor immune response that would typically attempt...
Approved
Investigational
Matched Description: … those of the skin, lung, kidneys, and liver. ... [L33320] PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - ... [A234379] Agents acting on the PD-1 pathway, such as [nivolumab] and [pembrolizumab], facilitate endogenous …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Rezafungin

Rezafungin is an echinocandin antifungal drug.[A258393,L45633] Unlike other echinocandins such as caspofungin and micafungin, rezafungin has long‐acting pharmacokinetics and a high stability that allows for it to have long dosing intervals maintaining high plasma exposure. Rezafungin has a half-life higher than 130 hours and can be administered once a week...
Approved
Investigational
Matched Description: … _Candida tropicalis_, as well as other _Candida_ and _Aspergillus_ spp. ... Rezafungin has a half-life higher than 130 hours and can be administered once a week instead of daily ... pharmacokinetics and a high stability that allows for it to have long dosing intervals maintaining high …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Sutilain

Sutilain is a member of the keratase family which includes agents such as papain. It is able to dissolve the intercellular matrix which helps with desquamation. Sutilain contains proteolytic enzymes derived from Bacillus subtilis and it is available as a cream-colored odorless powder. One gram of sutilain powder contains 250,000...
Approved
Withdrawn
Matched Description: … [T169] Sutilain was developed by Abbott and FDA approved on June 12, 1969. ... Sutilain contains proteolytic enzymes derived from _Bacillus subtilis_ and it is available as a cream-colored …
Matched Categories: … Enzymes and Coenzymes …

Efalizumab

Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It was later withdrawn...
Approved
Investigational
Withdrawn
Matched Description: … Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Mirikizumab

Mirikizumab is a monoclonal antibody developed by Eli Lilly intended to treat ulcerative colitis. It inhibits the actions of interleukin-23 (IL-23), a pro-inflammatory cytokine that activates pathways contributing to the development of inflammatory diseases.[L46237,L46257] Mirikizumab is approved in Japan and received a positive opinion from the EMA's Committee for Medicinal...
Approved
Investigational
Matched Description: … [L46252] It was officially approved in the EU in May 2023[L48656] and Canada in July 2023[L48661], and ... [L46237,L46257] Mirikizumab is approved in Japan[L46252] and received a positive opinion from the …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Displaying drugs 601 - 625 of 14608 in total